HSBC Holdings’s Denali Therapeutics DNLI Stock Holding History

HSBC Holdings’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,004	Closed	-$201K	–	2989
2025 Q3	$201K	Buy	14,004 +3,956	+39%	+$56.8K	﹤0.01%	2497
2025 Q2	$141K	Sell	10,048 -47,955	-83%	-$675K	﹤0.01%	2781
2025 Q1	$779K	Buy	58,003 +24,613	+74%	+$472K	﹤0.01%	1865
2024 Q4	$680K	Buy	33,390 +6,507	+24%	+$167K	﹤0.01%	2003
2024 Q3	$779K	Sell	26,883 -2,759	-9%	-$68.4K	﹤0.01%	1801
2024 Q2	$668K	Buy	29,642 +13,454	+83%	+$258K	﹤0.01%	1842
2024 Q1	$332K	Sell	16,188 -704	-4%	-$13.2K	﹤0.01%	2371
2023 Q4	$364K	Sell	16,892 -535	-3%	-$10.6K	﹤0.01%	2195
2023 Q3	$359K	Buy	+17,427	New	+$442K	﹤0.01%	2120
2023 Q2	–	Sell	-13,553	Closed	-$311K	–	2608
2023 Q1	$311K	Buy	13,553 +4,204	+45%	+$116K	﹤0.01%	2219
2022 Q4	$256K	Buy	9,349 +1,675	+22%	+$49.8K	﹤0.01%	2647
2022 Q3	$239K	Buy	+7,674	New	+$249K	﹤0.01%	2531

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HSBC Holdings's DNLI Position: Q4 2025 in Review

HSBC Holdings sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 14,004 shares — an estimated $201K sold.

HSBC Holdings first reported a position in DNLI in Q3 2022 and held it in 12 quarters. The position peaked at $779K in Q3 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

HSBC Holdings reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
HSBC Holdings sold 14,004 Denali Therapeutics shares in Q4 2025, an estimated $201K.
HSBC Holdings first reported a position in Denali Therapeutics in Q3 2022 and held it in 12 quarters.
HSBC Holdings's Denali Therapeutics position peaked at $779K in Q3 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.